aibio
Distress ·
Emergent BioSolutions posts $180.2 million Q2 loss, cuts about 90 roles
A $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring.
EBS Emergent BioSolutions Inc.
Emergent BioSolutions (EBS) news EBS lawsuit, settlement and buyback news
Latest Emergent BioSolutions news
- Debt Financing
Emergent BioSolutions closes $150 million term loan with OrbiMed, cuts ABL revolver to $50 million
Emergent drew a $150 million term loan with OrbiMed as administrative agent and repaid its prior credit agreement. Interest is Term SOFR plus 6.25%, with a 3.00% floor, and the loan matures as late as April 16, 2031. The asset-based revolver falls from $100 million to $50 million.
- Debt Financing
Emergent BioSolutions draws $150 million OrbiMed term loan, repays prior credit agreement
The Credit Agreement also provides a $75 million delayed draw term loan, available for 24 months. Interest is Term SOFR plus 6.25% per annum, with a 3.00% floor.
- Legal
Emergent BioSolutions derivative lawsuit settlement gets preliminary court approval
The U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025.
- Financings
Emergent BioSolutions authorizes repurchase of up to $50 million of stock
The board approved the Share Repurchase Program on March 31, 2025. The 8-K says the full terms are in a press release attached as Exhibit 99.1, and the 8-K body gives none of them.
What Emergent BioSolutions does
Emergent BioSolutions Inc. is a global life sciences company focused on preparedness and response solutions for public health threats, including chemical, biological, radiological, nuclear and explosives threats, emerging infectious diseases, emerging health crises, and acute, emergency and community care. The company says its portfolio includes 11 products addressing threats such as smallpox, mpox, anthrax, Ebola and opioid overdose emergencies. Its commercial products are the naloxone nasal sprays NARCAN and KLOXXADO, sold in the U.S. and Canadian markets. NARCAN is sold over the counter, while KLOXXADO is a prescription product sold at pharmacies and to public and government entities. Its medical countermeasure business focuses primarily on procurement by the U.S. government, its largest customer, and also covers anthrax and smallpox products. Its Bioservices business provides drug substance manufacturing, drug product fill and finish, packaging and development services. The company has sold several operations, including its travel health business to Bavarian Nordic and its Baltimore-Bayview drug substance facility to Syngene, and it acquired exclusive commercial rights to KLOXXADO from Hikma in the U.S. and Canada.
| Product or program | What it is | Stage |
|---|---|---|
| NARCAN Nasal Spray | Naloxone nasal spray for opioid overdose emergencies | commercial; sold over the counter |
| KLOXXADO Nasal Spray | Prescription naloxone nasal spray sold through pharmacies and government entities | commercial |
| Anthrax MCM products | Medical countermeasures for anthrax, procured mainly by the US government | |
| Smallpox MCM products | Medical countermeasures for smallpox, procured mainly by the US government | |
| Bioservices (CDMO) | Contract drug substance, fill and finish, packaging and development services |
Emergent BioSolutions annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $742.9 million | $1.04 billion |
| Research and development | $53.2 million | $70.7 million |
| Net income (loss) | $52.6 million | -$190.6 million |
| Cash from operations | $170.6 million | $58.7 million |
| Cash and equivalents | $205.4 million | $99.5 million |
Questions about Emergent BioSolutions
Is Emergent BioSolutions involved in a lawsuit?
Our latest story on this, dated May 23, 2025: "Emergent BioSolutions derivative lawsuit settlement gets preliminary court approval". The story links the filing or release it is based on. Read the story.
Has Emergent BioSolutions settled a lawsuit?
Our latest story on this, dated May 23, 2025: "Emergent BioSolutions derivative lawsuit settlement gets preliminary court approval". The story links the filing or release it is based on. Read the story.
Does Emergent BioSolutions have a share buyback?
Our latest story on this, dated Mar 31, 2025: "Emergent BioSolutions authorizes repurchase of up to $50 million of stock". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Emergent BioSolutions?
Emergent BioSolutions Inc. trades under the ticker EBS on NYSE.
Where is Emergent BioSolutions listed?
Emergent BioSolutions Inc. is listed on NYSE. Our directory also records these other listings: GETTEX:ER4; LS:A0LC2W; LSE:0IGA; LSX:A0LC2W.
What is the SEC CIK of Emergent BioSolutions?
The SEC Central Index Key (CIK) for Emergent BioSolutions Inc. is 1367644. Its filings are on SEC EDGAR.
How many shares does Emergent BioSolutions have outstanding?
51,273,336 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Emergent BioSolutions listed under?
Our directory records Emergent BioSolutions Inc. under United States.
What does Emergent BioSolutions do?
Our directory classifies Emergent BioSolutions Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Emergent BioSolutions?
The ISIN recorded for Emergent BioSolutions Inc. is US29089Q1058.
Does aibio.space cover Emergent BioSolutions?
aibio.space lists Emergent BioSolutions Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Emergent BioSolutions incorporated?
SEC records list its state or country of incorporation as DE.
What does Emergent BioSolutions develop?
Emergent BioSolutions Inc. is a global life sciences company focused on preparedness and response solutions for public health threats, including chemical, biological, radiological, nuclear and explosives threats, emerging infectious diseases, emerging health crises, and acute, emergency and community care. The company says its portfolio includes 11 products addressing threats such as smallpox, mpox, anthrax, Ebola and opioid overdose emergencies.
What is NARCAN Nasal Spray from Emergent BioSolutions?
NARCAN Nasal Spray: Naloxone nasal spray for opioid overdose emergencies Stage: commercial; sold over the counter.
What is KLOXXADO Nasal Spray from Emergent BioSolutions?
KLOXXADO Nasal Spray: Prescription naloxone nasal spray sold through pharmacies and government entities Stage: commercial.
Investor discussion: Emergent BioSolutions
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,9.01). Source
- Financings
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,7.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
- Financings
Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
SEC filings and registration
- SEC name
- Emergent BioSolutions Inc.
- CIK
- 1367644
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- EBS (NYSE)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
- Phone
- 240-631-3200
- Shares outstanding
- 51,273,336 as of 2026-07-30 (10-Q filed 2026-08-06)
Recent filings
Listing details
- Company
- Emergent BioSolutions Inc.
- Ticker
- EBS
- Listing
- NYSE
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US29089Q1058
- Other listed symbols
- GETTEX:ER4; LS:A0LC2W; LSE:0IGA; LSX:A0LC2W
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction